Cartesian Q3 net loss $35.9M; cash $145.1M; AURORA trial on track

Cartesian Therapeutics, Inc.

2025-Q3 EPS reported -$1.45 revenue$1,850,000

Net loss of $35.9M ($1.38/share) vs $24.2M ($1.13/share) in Q3 2024.
Cash, equivalents and restricted cash $145.1M, expected to fund ops into mid-2027.
Phase 3 AURORA enrollment on track; ~100 participants, primary endpoint at Month 4.
Preliminary Phase 2 SLE data and pediatric basket trial initiation expected by end of 2025.
R&D expense $13.8M (+21% YoY) due to AURORA trial and headcount growth.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001453687-25-000119
form_type: 8-K
ticker: RNAC
cik: 0001453687
company_name: Cartesian Therapeutics, Inc.
filed_at: 2025-11-06T23:59:59+00:00
discovered_at: 2026-05-14T18:02:39.444479+00:00
generated_at: 2026-05-16T23:35:47.076009+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001453687-25-000119
json_url: https://secwatch.observer/filing/0001453687-25-000119.json
markdown_url: https://secwatch.observer/filing/0001453687-25-000119.md
text_url: https://secwatch.observer/filing/0001453687-25-000119.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000119/0001453687-25-000119-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000119/rnac-20251106.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001453687-25-000119

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.